Altimmune, Inc.
Altimmune reports positive Phase 2b trial results.
1 source·19/12, 11:34·sec.gov
CEO transition announced with potential uncertainty.
1 source·01/12, 13:02·sec.gov
New $200 million equity distribution agreement initiated.
1 source·06/11, 21:32·sec.gov
10-Q form submitted!
1 source·06/11, 21:18·sec.gov
Altimmune secures increased loan funding from Hercules Capital.
1 source·06/11, 12:06·sec.gov
Dr. Harris retires; new CMO appointed.
1 source·03/10, 20:04·sec.gov
Annual Meeting results and director elections disclosed.
1 source·25/09, 20:08·sec.gov
10-Q form submitted!
1 source·12/08, 14:16·sec.gov
Altimmune announces Q2 2025 financial results.
1 source·12/08, 11:12·sec.gov
Altimmune reports positive results from Phase 2b trial.
1 source·26/06, 11:34·sec.gov
Altimmune Announces First Quarter 2025 Financial Results and Business Update
·finviz.com·13/05, 11:03
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
·finviz.com·13/05, 11:03
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress
·finviz.com·08/05, 11:36
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
·finviz.com·06/05, 11:35